STOP-T1D Low-Dose (ATG)
Public ClinicalTrials.gov record NCT04291703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
Study identification
- NCT ID
- NCT04291703
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- Antithymocyte Globulin Drug
- Placebo (for ATG) Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 34 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2023
- Primary completion
- Dec 16, 2024
- Completion
- Dec 16, 2024
- Last update posted
- May 6, 2026
2023 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Orange County | Orange | California | 92868 | — |
| University of California - San Francisco | San Francisco | California | 94143 | — |
| Stanford University | Stanford | California | 94305 | — |
| Barbara Davis Center at University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06511 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of South Florida Diabetes Center | Tampa | Florida | 33612 | — |
| Emory Children's Center | Atlanta | Georgia | 30322 | — |
| Indiana University - Riley Hospital for Children | Indianapolis | Indiana | 46202 | — |
| Children's Hospital of Iowa | Iowa City | Iowa | 52242 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| The Children's Mercy Hospital | Kansas City | Missouri | 64108 | — |
| Columbia University-Naomi Berrie Diabetes Center | New York | New York | 10032 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | — |
| Prisma Health | Greenville | South Carolina | 29615 | — |
| Vanderbilt Eskind Diabetes Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
| Benaroya Research Institute | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04291703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04291703 live on ClinicalTrials.gov.